Cargando…

Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome—A Single Center Prospective Study

Severe nephrotic syndrome (NS) is associated with high risk of venous thromboembolic events (VTE), as well as presumably altered heparin pharmacokinetics and pharmacodynamics. Although prophylactic anticoagulation is recommended, the optimal dose is not established. The aim of the study was to test...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matyjek, Anna, Rymarz, Aleksandra, Nowicka, Zuzanna, Literacki, Slawomir, Rozmyslowicz, Tomasz, Niemczyk, Stanislaw
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658079/ https://www.ncbi.nlm.nih.gov/pubmed/34884411 http://dx.doi.org/10.3390/jcm10235709

Ejemplares similares

Protein energy-wasting associated with nephrotic syndrome – the comparison of metabolic pattern in severe nephrosis to different stages of chronic kidney disease
por: Matyjek, Anna, et al.
Publicado: (2020)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Advanced Chronic Kidney Disease is a Strong Predictor of Hypogonadism and is Associated with Decreased Lean Tissue Mass
por: Skiba, Ryszard, et al.
Publicado: (2020)

Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease Patients Not Treated with Dialysis
por: Romejko, Katarzyna, et al.
Publicado: (2022)

Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients
por: Romejko, Katarzyna, et al.
Publicado: (2023)

Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
por: Al Otaib, Nouf, et al.
Publicado: (2017)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Serum Osteoprotegerin Is an Independent Marker of Metabolic Complications in Non-DialysisDependent Chronic Kidney Disease Patients
por: Rymarz, Aleksandra, et al.
Publicado: (2021)

Impaired Kidney Function Associated with Increased Risk of Side Effects in Patients with Small Vessel Vasculitis Treated with Rituximab as an Induction Therapy
por: Rymarz, Aleksandra, et al.
Publicado: (2021)

Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study
por: Hakeam, Hakeam A., et al.
Publicado: (2020)

Testosterone Replacement Therapy in Chronic Kidney Disease Patients
por: Skiba, Ryszard, et al.
Publicado: (2022)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Prevention of venous thromboembolism with enoxaparin in bariatirc surgery
por: Woo, Hee Doo, et al.
Publicado: (2013)

The role of factor Xa inhibitors in venous thromboembolism treatment
por: Cabral, Katherine P, et al.
Publicado: (2015)

Safety of Enoxaparin as Venous Thromboembolism Prophylaxis After Rhytidectomy
por: Lisiecki, Jeffrey L., et al.
Publicado: (2019)

The complex treatment including rituximab in the Management of Catastrophic Antiphospholid Syndrome with renal involvement
por: Rymarz, Aleksandra, et al.
Publicado: (2018)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Heart Metastases of Clear Cell Renal Cell Carcinoma
por: Romejko, Katarzyna, et al.
Publicado: (2023)

Comparison of Skinfold Thicknesses and Bioimpedance Spectroscopy to Dual-Energy X-Ray Absorptiometry for the Body Fat Measurement in Patients With Chronic Kidney Disease
por: Rymarz, Aleksandra, et al.
Publicado: (2017)

The significance of metalloproteinase 3 (MMP-3), chemokine CXC ligand 13 (CXCL-13) and complement component C5a in different stages of ANCA associated vasculitis
por: Rymarz, Aleksandra, et al.
Publicado: (2021)

Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
por: Dybdahl, Daniel, et al.
Publicado: (2019)

Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery
por: Kushnir, Margarita, et al.
Publicado: (2022)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Application of dynamic optimisation for planning a haemodialysis process
por: Stecz, Wojciech, et al.
Publicado: (2019)

Noninfectious, Severe Cryoglobulinemic Vasculitis with Renal Involvement – Safety and Efficacy of Long-Term Treatment with Rituximab
por: Leśniak, Ksymena, et al.
Publicado: (2021)

Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease
por: Romejko, Katarzyna, et al.
Publicado: (2022)

Low Free Triiodothyronine as a More Sensitive Predictor of Survival Than Total Testosterone among Dialysis Men
por: Leśniak, Ksymena, et al.
Publicado: (2023)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency
por: Minami, Kentaro, et al.
Publicado: (2018)

Efficacy and Safety of Enoxaparin for Preventing Venous Thromboembolic Events following Urologic Laparoscopic Surgery
por: Nomura, Takeo, et al.
Publicado: (2013)

Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients
por: Abbas, Mohamed Sayed
Publicado: (2017)

The use of enoxaparin as venous thromboembolism prophylaxis in bariatric surgery: A retrospective cohort study
por: Altawil, Esraa, et al.
Publicado: (2022)

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
por: Lage, S, et al.
Publicado: (2006)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
por: Tahaineh, Linda, et al.
Publicado: (2018)

Abstract: Venous Thromboembolism Prevention Using Twice Daily Enoxaparin in Plastic Surgery Patients: A Prospective Clinical Trial
por: Pannucci, Christopher J., et al.
Publicado: (2017)

Application of the Molecular Adsorbent Recirculating System in Type 1 Hepatorenal Syndrome in the Course of Alcohol-Related Acute on Chronic Liver Failure
por: Kade, Grzegorz, et al.
Publicado: (2020)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis
por: Xing, Jiali, et al.
Publicado: (2018)

Ethical Concerns Regarding High-Dose Enoxaparin for Venous Thromboembolism Prevention in Plastic Surgery Patients
por: Swanson, Eric
Publicado: (2019)

Low lean tissue mass can be a predictor of one-year survival in hemodialysis patients
por: Rymarz, Aleksandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cf67bk6ha1o7a7sln10quq67q6